Xenetic Biosciences (XBIO) to Release Earnings on Tuesday

Xenetic Biosciences (NASDAQ:XBIO) is projected to announce its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect the company to announce earnings of ($0.52) per share and revenue of $0.69 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 4:00 PM ET.

Xenetic Biosciences Stock Performance

Shares of NASDAQ:XBIO opened at $2.31 on Tuesday. Xenetic Biosciences has a one year low of $1.90 and a one year high of $13.93. The stock has a market capitalization of $5.29 million, a price-to-earnings ratio of -1.13 and a beta of 2.26. The company has a 50-day simple moving average of $2.30 and a 200-day simple moving average of $2.86.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Reduce”.

Institutional Trading of Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC purchased a new position in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned 0.60% of Xenetic Biosciences as of its most recent SEC filing. Institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.